These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 34873228)
1. The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials. Garofalo C; Capuano I; Pennino L; De Gregorio I; Riccio E; Provenzano M; Crocetto F; Buonanno P; Pandolfo SD; Andreucci M; Pisani A Sci Rep; 2021 Dec; 11(1):23500. PubMed ID: 34873228 [TBL] [Abstract][Full Text] [Related]
2. Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gevers TJ; Inthout J; Caroli A; Ruggenenti P; Hogan MC; Torres VE; Nevens F; Drenth JP Gastroenterology; 2013 Aug; 145(2):357-65.e1-2. PubMed ID: 23665274 [TBL] [Abstract][Full Text] [Related]
3. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial. Hogan MC; Chamberlin JA; Vaughan LE; Waits AL; Banks C; Leistikow K; Oftsie T; Madsen C; Edwards M; Glockner J; Kremers WK; Harris PC; LaRusso NF; Torres VE; Masyuk TV Clin J Am Soc Nephrol; 2020 Sep; 15(9):1267-1278. PubMed ID: 32843370 [TBL] [Abstract][Full Text] [Related]
4. Somatostatin analogues improve health-related quality of life in polycystic liver disease: a pooled analysis of two randomised, placebo-controlled trials. Neijenhuis MK; Gevers TJ; Nevens F; Hogan MC; Torres VE; Kievit W; Drenth JP Aliment Pharmacol Ther; 2015 Sep; 42(5):591-8. PubMed ID: 26129925 [TBL] [Abstract][Full Text] [Related]
5. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial. Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108 [TBL] [Abstract][Full Text] [Related]
6. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial. van Keimpema L; Nevens F; Vanslembrouck R; van Oijen MG; Hoffmann AL; Dekker HM; de Man RA; Drenth JP Gastroenterology; 2009 Nov; 137(5):1661-8.e1-2. PubMed ID: 19646443 [TBL] [Abstract][Full Text] [Related]
7. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease. van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH; Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403 [TBL] [Abstract][Full Text] [Related]
8. Long-acting somatostatin analogue treatments in autosomal dominant polycystic kidney disease and polycystic liver disease: a systematic review and meta-analysis. Griffiths J; Mills MT; Ong AC BMJ Open; 2020 Jan; 10(1):e032620. PubMed ID: 31924636 [TBL] [Abstract][Full Text] [Related]
9. Alkaline phosphatase predicts response in polycystic liver disease during somatostatin analogue therapy: a pooled analysis. Gevers TJ; Nevens F; Torres VE; Hogan MC; Drenth JP Liver Int; 2016 Apr; 36(4):595-602. PubMed ID: 26481454 [TBL] [Abstract][Full Text] [Related]
10. Somatostatin analog therapy effectiveness on the progression of polycystic kidney and liver disease: A systematic review and meta-analysis of randomized clinical trials. Suwabe T; Barrera FJ; Rodriguez-Gutierrez R; Ubara Y; Hogan MC PLoS One; 2021; 16(9):e0257606. PubMed ID: 34559824 [TBL] [Abstract][Full Text] [Related]
11. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206 [TBL] [Abstract][Full Text] [Related]
12. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. Hogan MC; Masyuk TV; Page LJ; Kubly VJ; Bergstralh EJ; Li X; Kim B; King BF; Glockner J; Holmes DR; Rossetti S; Harris PC; LaRusso NF; Torres VE J Am Soc Nephrol; 2010 Jun; 21(6):1052-61. PubMed ID: 20431041 [TBL] [Abstract][Full Text] [Related]
13. Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. Chrispijn M; Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Drenth JP J Hepatol; 2013 Jul; 59(1):153-9. PubMed ID: 23499726 [TBL] [Abstract][Full Text] [Related]
14. Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Hogan MC; Masyuk TV; Page L; Holmes DR; Li X; Bergstralh EJ; Irazabal MV; Kim B; King BF; Glockner JF; Larusso NF; Torres VE Nephrol Dial Transplant; 2012 Sep; 27(9):3532-9. PubMed ID: 22773240 [TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Meijer E; Drenth JP; d'Agnolo H; Casteleijn NF; de Fijter JW; Gevers TJ; Kappert P; Peters DJ; Salih M; Soonawala D; Spithoven EM; Torres VE; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Am J Kidney Dis; 2014 Mar; 63(3):446-55. PubMed ID: 24342522 [TBL] [Abstract][Full Text] [Related]
16. A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease. Seliger SL; Abebe KZ; Hallows KR; Miskulin DC; Perrone RD; Watnick T; Bae KT Am J Nephrol; 2018; 47(5):352-360. PubMed ID: 29779024 [TBL] [Abstract][Full Text] [Related]
17. Effect of everolimus on polycystic liver volume in autosomal dominant polycystic kidney disease. Zschiedrich S; Budde K; Walz G Clin Exp Nephrol; 2015 Aug; 19(4):757-8. PubMed ID: 25424440 [No Abstract] [Full Text] [Related]